How is Ozempic different from other GLP-1 medications
Results depend on the medication selected, dose tolerance, starting weight, nutrition habits, activity level, sleep, stress, metabolic health, and consistency with follow-up care
Long-term effects of exenatide therapy over 82 weeks on glycemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus
Degraded semaglutide may not produce the same clean GLP-1 receptor activation, potentially causing irregular GI symptoms
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes
Key Outcomes: Up to 24.2% total body weight reduction in high-dose groups